🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Shing M. Lee

Columbia University

ORCID: 0000-0001-8413-6869
MathematicsEconomics, Econometrics and FinanceMedicineBiochemistry, Genetics and Molecular BiologyDecision Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)”.

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

JCO Clinical Cancer Informatics(2023)10.1200/cci.22.00165
N/A
0.336DataRank · unranked
4 citations

Weijia Fan, Aijin Wang, Riha Vaidya, Mary W. Redman, Scott Gettinger +5 more

Misalignment between COVID-19 hotspots and clinical trial sites

Journal of the American Medical Informatics Association(2021)10.1093/jamia/ocab167
N/A
0.241DataRank · unranked
4 citations

Hao Liu, Mitchell S.V. Elkind, Muredach P. Reilly, Chunhua Weng, Shing M. Lee +1 more

Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials

JCO Precision Oncology(2021)10.1200/po.21.00136
N/A
0DataRank · unranked
5 citations

Christina Yap, Richard D. Carvajal, Shing M. Lee, Rebecca B. Silva

Impact of a Hospital-Based Specialty Pharmacy in Partnership With a Care Coordination Organization on Time to Delivery and Receipt of Oral Anticancer Drugs

JCO Oncology Practice(2022)10.1200/op.22.00451
N/A
0DataRank · unranked
6 citations

Morgan RL Lichtenstein, Rohit Raghunathan, Sahil D. Doshi, Shing M. Lee, Cynthia Law +5 more

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11531
N/A
0DataRank · unranked
1 citations

Shing M. Lee, Liner Ge, Mihaela Druta, Anthony P. Conley, Mary Louise Keohan +14 more

Precision Dose-finding Cancer Clinical Trials in the Setting of Broadened Eligibility

arXiv (Cornell University)(2023)10.48550/arxiv.2301.04578
N/A
0DataRank · unranked
0 citations

Bin Cheng, Richard D. Carvajal, Shing M. Lee, Rebecca B. Silva

Dose-finding designs for trials of molecularly targeted agents and immunotherapies

UNC Libraries(2020)10.17615/97xj-4d96
N/A
0DataRank · unranked
0 citations

Anastasia Ivanova, Jonathan Shtaynberger, Jimmy Duong, Gulam A. Manji, Chiuzan, Cody +2 more

Pragmatic, multicentre, factorial, randomised controlled trial of sepsis electronic prompting for timely intervention and care (SEPTIC trial): a protocol

BMJ Open(2025)10.1136/bmjopen-2024-088792
N/A
0DataRank · unranked
0 citations

Min Qian, Matthew J. Cummings, David Y. Zhang, Shing M. Lee, Jeremy R. Beitler +14 more

Selection of the initial design for the two-stage continual reassessment method

UNC Libraries(2020)10.17615/0kb4-bt23
N/A
0DataRank · unranked
0 citations

Shing M. Lee, Anastasia Ivanova, Xiaoyu Jia